Researchers have identified a new modification - glycerol phosphate - on the surface of the Group A Streptococcus bacterium. This opens up possibilities for developing a vaccine against this pathogen.
Most people think of "throat infection" as a relatively benign infection that can be cured by antibiotics and a few days of rest. However, the bacterium that causes throat infection - Group A Streptococcus (GAS) or Streptococcus pyogenes - is also responsible for much more dangerous conditions, including rheumatic heart disease and sepsis. With the specter of antimicrobial resistance and the large burden of disease (worldwide 500,000 deaths annually) caused by the bacteria, there is great urgency for developing a vaccine.
Potential target for streptococcal vaccine identified
The U.S.-based Antibacterial Resistance Leadership Group (ARLG), part of the Duke Clinical Research Institute (DCRI) and the University Medical Center (UMC) Utrecht, the managing entity of the COMBACTE (Combatting Bacterial Resistance in Europe) consortium, will work together to solidify a comprehensive global community to combat the threat of antibiotic resistance around the world.
This collaboration is expected to take several forms, including joint design and implementation of clinical research, working meetings at scientific conferences like the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), and IDWeek, cross-entity working groups with diverse functional group participation, clinical trial innovations, data and protocol exchanges, and, contractual, regulatory, and systems harmonization.
Organizations Join Forces to Create Global Alliance Against Antibiotic Resistance
je telefoon of tablet
om deze pagina te